Quick Links

Breadcrumbs Navigation

Home > Clinical Trials > Adult Clinical Trials - Genitourinary Cancers - Prostate cancer and cancers of the kidney, bladder, and male organs

Jumbo Large Regular Text:

Print E-mail

Clinical Trials

Adult Clinical Trials - Genitourinary Cancers - Prostate cancer and cancers of the kidney, bladder, and male organs

If you need additional information about any of trials for newly diagnosed or early stage disease please call Patricia Creel, RN at 919-668-0635. For advanced or metastatic disease please contact: Peggy Lyons at 919-668-0413.

Items 1 - 21 of 21

ISOLATION OF CIRCULATING TUMOR CELLS USING A NOVEL EMT-BASED CAPTURE METHOD
Principal Investigator: Andrew Armstrong
Phase: Phase I
Phone: 919-681-2162

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men with Castration-Resistant Heavily pre-treated Prostate Cancer
Principal Investigator: Andrew Armstrong
Phase: Phase I
Phone: 919-668-8577

A Phase II Study of BKM120 in Men with Metastatic Castration-Resistant Prostate Cancer.
Principal Investigator: Andrew Armstrong
Phase: Phase II
Phone: 919-668-0413

A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Principal Investigator: Andrew Armstrong
Phase: Phase II
Phone: 919-668-0413

Efficacy and Safety of oral Kanglaite (KLTc) Gelcap in Men with Prostate Cancer: Randomized, Dose-Ranging Study of the Effects of KLTc Gelcap (3 or 6 capsules four times/day) on Prostate Specific Antigen (PSA) Doubling Time Among Men with Rising PSA Levels after Definitive Local Therapy for Prostate Cancer.
Principal Investigator: Andrew Armstrong
Phase: Phase II
Phone: 919-668-0635

STRIVE: A Multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide vs. Bicalutamide in Men with Prostate Cancer who have Failed Primary Androgen Deprivation Therapy
Principal Investigator: Andrew Armstrong
Phase: Phase II
Phone: 919-668-0413

Whole Blood from Healthy Volunteers for the Study of Circulating Tumor Cells
Principal Investigator: Andrew Armstrong
Phase: Phase II
Phone: 919-681-2162

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men with Metastatic Castrate-Resistant Prostate Cancer.
Principal Investigator: Andrew Armstrong
Phase: Phase III
Phone: 919-668-0413

A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer
Principal Investigator: Andrew Armstrong
Phase: Phase IV
Phone: 919-668-0413

Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastasis
Principal Investigator: Rhonda Bitting
Phase: Phase II
Phone: 919-684-1390

Phase I/II Study of Docetaxel, Prednisone and Pazopanib in Men with Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and Poor-Risk Factors.
Principal Investigator: Daniel George
Phase: Phase I
Phone: 919-668-0413

A Phase II Biomarker Trial of Everolimus in Patients with Advanced Renal Cell Carcinoma
Principal Investigator: Daniel George
Phase: Phase II
Phone: 919-668-0413

A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy
Principal Investigator: Daniel George
Phase: Phase III
Phone: 919-668-0635

: A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER-2+ Urothelial Carcinoma
Principal Investigator: Michael Harrison
Phase: Phase II
Phone: 919-668-0635

A Phase 3, randomized, double-blind, controlled trial of cabozantinib (XL184) versus mitoxantrone plus prednisone in men with previously treated symptomatic castration-resistant prostate cancer
Principal Investigator: Michael Harrison
Phase: Phase III
Phone: 919-668-0413

A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Principal Investigator: Michael Harrison
Phase: Phase III
Phone: 919-668-0413

Exercise Training, Erectile Dysfunction, and Prostate Cancer
Principal Investigator: Lee Jones
Phase: Phase II
Phone: 919-684-5494

A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE III TRIAL TO EVALUATE THE EFFECTIVENESS OF A PHOSPHODIESTERASE 5 INHIBITOR, TADALAFIL, IN PREVENTION OF ERECTILE DYSFUNCTION IN PATIENTS TREATED WITH RADIOTHERAPY FOR PROSTATE CANCER
Principal Investigator: Bridget Koontz
Phase: Phase III
Phone: 919-668-3726

A Phase II Randomized Study For Patients With Muscle-Invasive Bladder Cancer Evaluating Transurethral Surgery And Concomitant Chemoradiation By Either BID Irradiation Plus 5-Fluorouracil And Cisplatin Or QD Irradiation Plus Gemcitabine Followed By Selective Bladder Preservation And Gemcitabine/Cisplatin Adjuvant Chemotherapy
Principal Investigator: William Lee
Phase: N/A
Phone: 919-668-3726

Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Principal Investigator: William Lee
Phase: N/A
Phone: 919-668-3726

A Phase II Study of Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer Using Continuous Real-time Evaluation of Prostate Motion and IMRT Plan Reoptimization based on the Same Day Anatomy
Principal Investigator: William Lee
Phase: Phase II
Phone: 919-668-3726